Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
BMJ Case Rep ; 14(3)2021 Mar 02.
Article in English | MEDLINE | ID: covidwho-1115111

ABSTRACT

We describe a case of retrovesical liposarcoma in a male patient with concurrent COVID-19. A 50-year-old man had lower urinary tract symptoms and dull pain along his right gluteus. Due to COVID-19 infection, management was delayed. During self-isolation, the patient developed urinary retention and his pain level was an eight on the Visual Analogue Scale. A urinary catheter and an epidural catheter were inserted without any difficulty. Abdominal-pelvic MRI revealed a retrovesical mass suspected of liposarcoma with clear borders from surrounding organs. Following two consecutive negative SARS-CoV-2 PCR tests, we proceeded with surgery. Histopathology was dedifferentiated liposarcoma. Postoperatively, the patient suffered reactivation of COVID-19, and he was eventually discharged after two consecutive negative results on the PCR test on Post Operative Day (POD)-10. Retrovesical dedifferentiated liposarcoma is rare and considered as high-grade liposarcoma. Although surgery may exacerbate COVID-19 infection, surgical resection of symptomatic high-grade sarcoma is prioritised and performed as soon as no infection detected.


Subject(s)
COVID-19/diagnosis , Liposarcoma , Lower Urinary Tract Symptoms , Pelvic Neoplasms , SARS-CoV-2/isolation & purification , Surgical Procedures, Operative/methods , Urinary Retention , COVID-19/therapy , Chemoradiotherapy, Adjuvant/methods , Dissection/methods , Humans , Liposarcoma/pathology , Liposarcoma/physiopathology , Lower Urinary Tract Symptoms/diagnosis , Lower Urinary Tract Symptoms/etiology , Magnetic Resonance Imaging/methods , Male , Middle Aged , Neoplasm Grading , Pelvic Neoplasms/pathology , Pelvic Neoplasms/physiopathology , Time-to-Treatment , Treatment Outcome , Urinary Retention/diagnosis , Urinary Retention/etiology
2.
Cancer Rep (Hoboken) ; 4(2): e1320, 2021 04.
Article in English | MEDLINE | ID: covidwho-967725

ABSTRACT

BACKGROUND: COVID-19 outbreak was declared as a pandemic by the World Health Organization in March 2020. Over the last 3 months, the pandemic has challenged the diagnosis and treatment of all cancer, including rectal cancer. Constraints in resources call for a change in the treatment strategy without compromising efficacy. RECENT FINDINGS: Delivery of shorter treatment schedules for radiotherapy offers advantages like short overall treatment time, improved throughput on the machine, improved compliance and reduced risk of transmission of COVID 19. Other strategies include delaying surgery, reducing the intensity of chemotherapy and adoption of organ preservation approach. CONCLUSION: The curative treatment of rectal cancer should not be hindered during the COVID pandemic, and modifications in the multi-modality treatment will help achieve quality care.


Subject(s)
COVID-19/prevention & control , Communicable Disease Control/standards , Pandemics/prevention & control , Radiation Oncology/organization & administration , Rectal Neoplasms/therapy , COVID-19/epidemiology , COVID-19/transmission , Chemoradiotherapy, Adjuvant/methods , Chemoradiotherapy, Adjuvant/standards , Humans , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Neoadjuvant Therapy/methods , Neoadjuvant Therapy/standards , Organ Sparing Treatments/methods , Organ Sparing Treatments/standards , Personal Protective Equipment/standards , Radiation Oncology/methods , Radiation Oncology/standards , Radiotherapy, Adjuvant/methods , Radiotherapy, Adjuvant/standards , Rectal Neoplasms/diagnosis , Telemedicine/methods , Telemedicine/organization & administration , Telemedicine/standards , Time Factors , Time-to-Treatment/standards , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL